RxSight, Inc. Reports Third Quarter 2026 Results

What happened

RxSight reported $24.6 million in revenue for the quarter ended September 30, 2026, primarily driven by sales of 23,128 Light Adjustable Lens units. It also reported $254.7 million in cash, cash equivalents and short-term investments, including $60 million received in the third quarter through its Alcon collaboration.

Confirmed

Global impact / market context

The reported revenue reflects sales of the company’s lens products, while its cash position provides funds for operations and investment. RxSight also said it nearly doubled its sales force and completed restructuring intended to save operating expenses, changes that could affect future selling costs and growth.

Analyst inference

The results combine commercial expansion with cost-cutting: more sales staff may support wider customer engagement, while restructuring is intended to reduce expenses in the core business. The Alcon collaboration also contributed $60 million in cash, but the article does not give its financial terms or future revenue impact.

Analyst inference

What to watch

1. Future quarterly revenue and lens-unit sales can show whether the expanded sales force and deeper practice support are translating into stronger customer demand. Analyst inference
2. RxSight said its restructuring is intended to generate operating expense savings; future expense disclosures can indicate whether those savings are achieved and sustained. Confirmed
3. The initial 120-day period under the Alcon agreement is complete; further updates could clarify the collaboration’s activity and any contribution to revenue or cash. Confirmed

Evidence

• globenewswire.com